BEAT-meso Trial Again Identifies Non-Epithelioid Mesothelioma as Distinct Population

Concurrent IO with Chemoradiotherapy: Insights from PACIFIC-2

Celebrate 5 Decades of the World Conference on Lung Cancer in San Diego’s Historic Gaslamp Quarter

2024 IASLC Academy to Once Again Compete in Amazing Case Race

Get Moving and Win During the 2024 Wellness Challenge

Know Before You Go: What You Need to Know to Get to—and Navigate—San Diego

LAURA Trial Defines Role of EGFR-directed Therapy in Unresectable Stage III NSCLC

ADRIATIC Demonstrates Meaningful Improvements in OS, PFS in Patients with Limited-stage SCLC

CROWN Results Demonstrate Longest Progression-Free Survival in Advanced NSCLC Seen to Date

Subcutaneous Amivantamab Leads to Unexpected OS Improvement vs. IV Dosing in Refractory, EGFR+ Advanced NSCLC

KRYSTAL-12 Supports Previous Evidence Showing Adagrasib is Superior to Docetaxel in Pretreated Advanced KRAS-mutated NSCLC

Investigators Report Efficacy, Safety Analysis of Tarlatamab in SCLC Patients With or Without Baseline Brain Metastases